| 0.175 -0.004 (-2.02%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.28 | 1-year : | 0.35 |
| Resists | First : | 0.24 | Second : | 0.3 |
| Pivot price | 0.19  |
|||
| Supports | First : | 0.16 | Second : | 0.13 |
| MAs | MA(5) : | 0.18 |
MA(20) : | 0.2 |
| MA(100) : | 0.29 |
MA(250) : | 0.71 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.2 |
D(3) : | 24 |
| RSI | RSI(14): 32.1 |
|||
| 52-week | High : | 3.43 | Low : | 0.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OGEN ] has closed above bottom band by 20.8%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.18 - 0.18 | 0.18 - 0.18 |
| Low: | 0.17 - 0.17 | 0.17 - 0.17 |
| Close: | 0.17 - 0.17 | 0.17 - 0.18 |
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Wed, 09 Apr 2025
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - GlobeNewswire
Mon, 07 Apr 2025
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - Yahoo Finance
Thu, 27 Mar 2025
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - GlobeNewswire
Tue, 18 Mar 2025
Going Concern Alert: Oragenics Brain Treatment Pipeline Faces Critical Financial Test - Stock Titan
Tue, 18 Mar 2025
Oragenics, Inc. Files Annual Report for 2024, Receives Unqualified Audit Opinion - Nasdaq
Fri, 14 Mar 2025
Oragenics Inc. (OGEN) reports earnings - Quartz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 4.72e+006 (%) |
| Held by Institutions | 12 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.964e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -263 % |
| Return on Assets (ttm) | 285.1 % |
| Return on Equity (ttm) | -219.9 % |
| Qtrly Rev. Growth | 7470 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -947.34 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -1.68 |
| Dividend | 0 |
| Forward Dividend | 1.32e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|